☆ 4.7 Meeting Abstract

First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours

ANNALS OF ONCOLOGY (2020)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 31, Issue -, Pages S707-S707

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2020.08.1145

Keywords

-

Categories

Oncology

Funding

  1. F. Hoffmann-La Roche Ltd.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.